The 6th Annual Cell Culture & Bioprocessing Congress 2017 was held on 6-7 November 2017 in London, UK.
The event had over 250 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions.
40 presentations, case studies and panel discussions focused on the key issues in cell line optimization, process development and biological production.
4 interactive streams:
- Early Cell Line Development
- Process Development
- Late Stage Cell Line Development
- Biological Production
14 pre-scheduled one to one meetings, exhibition and informal networking opportunities.
Dr. Jamie Freeman, Product Manager (Bioproduction) at Horizon spoke on "Engineering the next generation of CHO cells."
Aside from single gene knockouts to allow for metabolic selection systems, the CHO host itself remains largely unchanged from that which was used thirty years ago. Here I will present how we have used the recently released annotated sequence of our GS null CHO K1 cell line to design an optimized whole genome CRISPR library. Together with a range of reporter assays, and combined with hypothesis driven approaches we will identify genetic targets that improve the biomanufacturing capacity of our GS knockout CHO K1 cell line. Once identified, we can use rAAV based gene engineering technology to generate edited cell line with a clear IP position and the freedom to use the cells for commercial manufacturing.